PubMed Health⌕ Search

Biomedical subjects

X Le Loet

Publications and source records attributed to X Le Loet.

At least 19 recordsLinked to original sources
PubMed1992

VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).

A randomized trial has been performed in which 91 patients with stage III myeloma and additional severe criteria were randomly allocated to either VAD or VMBCP. No significant difference was noted between these two groups using the following criteria: response rate (VMBCP: 54%; VAD: 39%), impact on symptoms, median survival (VMBCP: 14 months, VAD: 17 months). However, toxic effects and refusal to pursue treatment were more frequent with VAD than with VMBCP (12 v 6). Therefore, in this trial, VMBCP appears to be more useful than VAD.

Adult↗
PubMed1992

Analysis of T cell receptors in rheumatoid arthritis: the increased expression of HLA-DR antigen on circulating gamma delta+ T cells is correlated with disease activity.

The phenotypic characteristics of peripheral blood T cells, isolated from 37 rheumatoid arthritis (RA) patients and 17 healthy controls were determined with special emphasis on gamma delta+ T cells and CD4-CD8- alpha beta+ T cells. Two- and three-colour automated flow cytometry analyses were performed using a panel of MoAbs directed against differentiation antigens and T cell receptor molecules. The results demonstrated: (i) no significant difference between the percentages of CD4-CD8- alpha beta+ T cells in patients and controls; (ii) a significant decrease of the gamma delta+ T cell level in the peripheral blood of RA patients relative to controls; (iii) phenotypic abnormalities of circulating gamma delta+ T cells in RA patients suggestive of an activation status in vivo. These abnormalities included a significant reduction in the density of the T cell differentiation antigen CD3 and an increase in the expression of HLA-DR antigen. The level of circulating HLA-DR+/gamma delta+ T cells was significantly higher in patients with active disease. HLA-DR+/gamma delta+ T cells were also present in the synovial fluid obtained from three patients with an active disease. In addition, preliminary experiments showed that the activated gamma delta+ T cells were predominantly V delta 1. Taken together, these data support the involvement of gamma delta+ T cells in the pathogenesis of RA.

Adult↗
PubMed1991

Anti-myeloperoxidase antibodies: immunological characteristics and clinical associations.

Antibodies directed against myeloperoxidase (anti-MPO) were detected, using a solid-phase ELISA and purified sputum myeloperoxidase as the substrate, in 54 sera from 22 patients. Anti-MPO were present in 17 patients with crescentic glomerulonephritis (CGN), Wegener's granulomatosis (WG) and microscopic polyarteritis (MPA), and thus are associated with different forms of vasculitis. Anti-MPO were also present in five out of 20 patients with systemic lupus erythematosus (SLE). Anti-MPO activity in SLE sera was low, in contrast to the high titers observed in patients with vasculitis. All positive sera had IgG anti-MPO (except two SLE sera) and most of them also contained low-titered IgM anti-MPO. Only three patients had high IgM anti-MPO activities, the significance of which remains to be determined. In patients with CGN, WG or MPA, the anti-MPO titer decreased following therapy and paralleled the disease activity. Thus, anti-MPO constitute a useful diagnostic tool and a sensitive marker of disease activity in this group of patients with vasculitis.

Arteritis↗
PubMed1990

[Social impact of osteoarthritis. Risk/benefit--cost/effectiveness ratio of osteoarthritis treatments].

The development of a drug for the fundamental treatment of osteoarthritis requires that its efficacy should be proven clinically. This implies that there must be a clear definition of the evaluation criterion (slowing down in the progression of osteoarthritic lesions). Marketing of a drug depends on the efficacy/safety relationship, but any assessment of the value of a fundamental treatment for osteoarthritis goes beyond the framework of a study of its efficacy. Its usefulness can be measured in terms of scales estimating the quality of life that are related to the osteoarthritic disease. Overall criteria, such as the level of maintenance treatment, can be used in comparative, randomized, double blinds trials. Pragmatic trials seem to afford a methodology which is suited to the evaluation of usefulness and therapeutic benefit. The basis of cost/effectiveness, cost/usefulness and cost/benefit studies relies on a comparison of the cost of osteoarthritis and its treatment with the benefits brought about by such treatment.

Cost-Benefit Analysis↗
PubMed1989

Safety of ketoprofen in the elderly: a prospective study on 20,000 patients.

Safety is a major concern in drug therapy in the elderly. NSAIDs are often used in the elderly and may induce side-effects. With a view to monitor the safety profile of ketoprofen, 19,880 patients greater than 60 years of age were enrolled in a large scale open study. They received a 200 mg sustained release tablet once-a-day for one month, in almost all cases for osteoarthritis. Patients mean age was 72.2 +/- 6.7 years. At the end of treatment, overall efficacy was rated as excellent or good in 70.7% of cases by patients and 74.2% by physicians. Tolerability was judged excellent: 60.8%; good: 24.0%; moderate: 8.7%; and poor: 5.1%. Side-effects related to ketoprofen occurred in 15.3% of patients and led to withdrawal in 4.5%. The most frequent side-effects were related to the G.I. tract (13.5% of total patients). Severe G.I. side-effects (ulcer, melena) occurred in 0.03%. Skin side-effects occurred in 0.7% and were always benign. No relationship was found between the incidence of side-effects and age or dosing time. In contrast, a higher incidence of side-effects was demonstrated in women, in case of associated disorders or concomitant therapy and in patients previously treated with other NSAIDs. In conclusion, in this very large population of elderly patients, ketoprofen had a good risk/benefit ratio.

Aged↗
PubMed1988

Serum hyaluronate in rheumatoid arthritis: study by affino-immunoenzymatic assay.

Serum level of hyaluronate (HA) was assayed by an affino-immunoenzymatic method using hyaluronectin, in 25 patients with rheumatoid arthritis (RA), 24 patients with ankylosing spondylitis (AS) and 103 controls. The mean serum HA level was significantly higher (p less than 0.001) in RA (171 +/- 39 micrograms/l) than in controls (22.4 +/- 1.6 micrograms/l) and AS patients (30.3 +/- 3.0 micrograms/l). The mean HA level in RA on corticosteroids (98.2 +/- 25.9 micrograms/l) was significantly lower (p less than 0.05) than that of RA without steroids (220.1 +/- 60.5 micrograms/l). The serum HA levels were not correlated with clinical or serological indicators of inflammatory activity. This increase in serum HA probably reflected an excessive production by rheumatoid synovium and not a lowered catabolism, all patients having normal hepatic function. The origin of the increased synthesis is still unknown. These results suggest that serum hyaluronate is not a universal indicator of inflammation but is perhaps a characteristic of RA.

Adolescent↗
PubMed1988

[The epidemiology of multiple myeloma in France].

From mortality and population data provided by INSERM and INSEE, we have determined the mortality rate of multiple myeloma--uncorrected, specific and standardized rates--which have enabled to conduct an epidemiological, demographic, geographic and chronological study. The demographic study done in 1981-1982, confirms that the incidence of multiple myeloma is linked to ageing and that it is higher in men. The geographic study does not find any preferential regional distribution. The chronological survey done between 1958 and 1982, shows an increased mortality rate of about 500 p. cent and this increase is seen exclusively in patients over 55. Such progression analyzed according to the model age, period, cohort, is either compatible with a cohort effect, reflection of a true incidence increase, or with a period effect depending upon age, reflection of an artificial increase linked to modifications of hygiene conditions. This last factor seems to predominate. Anyway, decreased mortality rates have been observed for the most recent generations, which should, in the future, mean a stagnation or even a decrease in the incidence of multiple myeloma.

Adult↗